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Objective: Sulfonylureas, the first available drugs for the management of type 2 diabetes, 
remain widely prescribed today. However there exists significant variability in glycaemic 
response to treatment. We aimed to establish heritability of sulfonylurea response and 
identify genetic variants and interacting treatments associated with HbA1c reduction.  
Research design and methods: As an initiative of the Metformin Genetics Plus (MetGen Plus) 
and the DIabetes REsearCh on patient straTification (DIRECT) consortia, 5,485 white 
Europeans with type 2 diabetes treated with sulfonylurea were recruited from 6 referral 
centres in Europe and North America. We first estimated heritability using generalized 
restricted maximum likelihood (REML) and then undertook GWAS of glycemic response to 
sulfonylureas measured as HbA1c reduction after 12 months of therapy followed by meta-
analysis. These results were supported by acute glipizide challenge in humans who were 
naïve to type 2 diabetes medications, cis-eQTLs and functional validation in cellular models. 
Finally, we examined for a possible drug-drug-gene interactions.  
Results: After establishing that sulfonylurea response is heritable (37±11%), we identified 
two independent loci near the GXYLT1 and SLCO1B1 genes associated with HbA1c 
reduction at a genome-wide scale (p < 5×10-8). The C-allele at rs1234032, near GXYLT1, was 
associated with 0.14% (1.5 mmol/mol), p=2.39×10−8) lower reduction in HbA1c. Similarly, 
the C-allele was associated with higher glucose trough levels (β=1.61, p=0.005) in healthy 
volunteers in the SUGAR-MGH given glipizide (N = 857). In 3, 029 human whole blood 
samples, the C-allele is a cis-eQTL for increased expression of GXYLT1 (β=0.21, p=2.04×10-
58). The C-allele of rs10770791, in an intronic region of SLCO1B1, was associated with 
0.11% (1.2 mmol/mol) greater reduction in HbA1c (p=4.80×10−8). In 1,183 human liver 
samples, the C-allele at rs10770791 is a cis-eQTL for reduced SLCO1B1 expression 
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(p=1.61×10−7) which, together with functional studies in cells expressing SLCO1B1, supports 
a key role for hepatic SLCO1B1 (encoding OATP1B1) in regulation of sulfonylurea 
transport. Further, a significant interaction between statin use, sulfonylurea response and 
SCLO1B1 genotype was observed (p=0.001). In statin non-users, C-allele homozygotes at 
rs10770791 had a large absolute reduction in HbA1c (0.48±0.12% (5.2±1.26 mmol/mol)), 
equivalent to initiating a DPP4 inhibitor. 
Conclusion: We have identified clinically important genetic effects at genome wide levels of 
significance, and important drug-drug-gene interactions, which include commonly prescribed 
statins. With increasing availability of genetic data embedded in clinical records these 
















Sulfonylureas are potent glucose-lowering drugs that reduce HbA1c by an average of 1.5% 
(18 mmol/mol) (1). Despite an increasing trend to use more modern, expensive treatments, 
sulfonylureas remain commonly prescribed in the UK, making up 27% of new prescriptions, 
second only to metformin (2). Due to their very low cost, they are extensively used in low- 
and middle-income countries.  However, considerable variation exists in response to 
sulfonylureas, with 10-20% of people with diabetes not responding at initiation of 
sulfonylurea therapy and 30-35% failing to respond to monotherapy after 5 years (3, 4). It is 
likely that a combination of genetic and non-genetic modifying factors underlies the clinical 
variability of glycaemic response to sulfonylureas. While many clinical risk factors such as 
baseline HbA1c, sex, duration of diabetes and dose are associated with glycemic response to 
sulfonylureas (5-7), modulatory genetic factors remain largely unexplored with the exception 
of a few proof-of-concept studies using a candidate gene approach (8-12).  
Glycemic response to metformin is heritable with 34% of the variance in response 
explainable by common genetic variants (13-15). There have been no similar estimates for 
sulfonylurea response and to date, no genome-wide association studies (GWAS) of glycemic 
response to sulfonylurea treatment have been reported, so the genetic contribution to how 
patients respond to sulfonylureas and clinical implication of this genetic variation has not 
been systematically studied. As an initiative of the Metformin Genetics Plus (MetGen Plus) 
and the DIabetes REsearCh on patient straTification (DIRECT) consortia, we report here the 
first genome-wide meta-analysis of glycemic response to sulfonylureas measured as HbA1c 
reduction after 12 months of therapy. Based upon these findings we then explore the impact 
of interacting drugs and identify clinically important genotype dependent statin-sulfonylurea 




List of abbreviations used throughout this article and their corresponding explanations are 
shown in Supplementary Table 1. 
Study design and participants 
We established an international consortium allowing recruitment of 5,485 unrelated 
individuals of European ancestry from six referral centers in Europe and North America as 
part of the MetGen and DIRECT consortia (Supplementary Table 2). Included participants 
had a clinical diagnosis of type 2 diabetes and were treated with sulfonylureas as 
monotherapy or as an add-on to metformin. This study was approved by respective research 
ethics review boards and participants provided written informed consent. 
 
Sample ascertainment 
Clinical, prescription and biochemical data were retrieved from the electronic medical record 
systems. Participants with type 2 diabetes aged more than 35 years at diagnosis who used 
sulfonylureas with no history of insulin use were ascertained. They were stably treated with 
sulfonylureas for at least six months with no other glucose-lowering drug started or stopped 
within the study period. The baseline HbA1c was between 7% (53.0 mmol/mol) and 14% 
(129.5 mmol/mol) at sulfonylurea initiation.  
 
Measurement of glycemic response and definition of variables 
Participants’ glycemic response to sulfonylurea was modelled as the quantitative phenotype 
of HbA1c reduction between baseline HbA1c and treatment HbA1c while the patients were 
maintained on stable treatment. Baseline HbA1c was defined as the closest HbA1c measure 
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to sulfonylurea initiation and within six months before and seven days after this date. The 
treatment HbA1c was the closest HbA1c measure to 12 months after initiation of 
sulfonylureas (between 6 and 15 months).  
In all the studies, covariates were selected based on previous reports and univariate 
association between the outcome variable (HbA1c reduction) and explanatory variables. The 
best fit linear regression model was determined using stepwise backward elimination. 
Accordingly, baseline HbA1c, sex, age at diagnosis, baseline BMI, average daily dose, time 
between baseline HbA1c and treatment HbA1c and drug group (sulfonylurea monotherapy or 
sulfonylurea added to metformin) were considered in the final model as available in each 
cohort (Supplementary Table 3). Average daily dose was calculated as the mean daily dose of 
prescriptions filled during the study period (mean of percentage of each sulfonylurea divided 
by maximum prescribable according to the British National Formulary). Baseline weight was 
the nearest measure to the sulfonylurea start date (index date) and within 180 days on either 
side of the index date. Each study was adjusted for the top n principal components (PCs) to 
account for 80~90% of the variation in population structure. 
The final response model was: HbA1c reduction ~ baseline HbA1c + PCs + study specific 
covariates. 
 
Genome-wide array genotyping, quality control and imputation  
Each respective cohort performed genome-wide genotyping on a variety of arrays as 
illustrated in Supplementary Table 3. Genotyping and quality-control procedures for the 
GoDARTS, DCS, and PMET cohorts has been previously described (13, 15, 16). Genotyping 
data for each platform were individually cleaned by each study center. Standard post-
genotyping quality-control procedures were applied to each data set (Supplementary Figure 
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1). Monomorphic, SNPs with minor allele frequency (MAF)<1% or call rate <98% or Hardy-
Weinberg equilibrium (HWE) <10-6 were removed. Samples with genotyping calls <98% or 
heterozygosity >3 standard deviation from the mean or correlated with another sample 
(Identity by descent >0.125) were filtered out. All genetic variants were mapped to and 
reported using Genome Reference Consortium Human genome build 37 (GRCh37). Each 
data set was then imputed to the 1000 Genome CEU reference panel (phase 1, version 3) with 
IMPUTE software (17), except PMET2 and Geisinger where imputation was performed using 
the HRC.r1-1 EUR reference genome (GRCh37 build) using the Michigan server. Post-
imputation, SNPs with poor imputation quality (Info < 0.6), monomorphic variants or MAF < 
5% were excluded (Supplementary Figure 1). 
 
Genome-wide association analysis  
Following imputation, each respective cohort conducted GWAS under an additive genetic 
model to assess the role of common variants (MAF ≥ 5%) in glycemic response to 
sulfonylureas. Each SNP was tested for association with quantitative measure of sulfonylurea 
related HbA1c reduction with SNPTEST v2.536 (18) using multiple linear regression 
correcting for baseline HbA1c, genotypic PCs and other study specific variables 
(Supplementary Table 3). Genome-wide association analyses were carried out separately by 
respective study centers. Prior to meta-analysis, we performed post-GWAS harmonization 
and QC of GWAS results from each cohort to track possible errors in the study-specific 
analyses. We used the standard protocol accompanied by EasyQC R package (19). 
Specifically, we removed SNPs with MAF < 5%, low imputation quality (< 0.6), large 
absolute values of beta coefficients and standard errors (≥10), low call rate (< 0.98), and 
deviations from HWE (p < 10− 6). Meta-analysis was then performed using an inverse 
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variance weighted fixed effect model, implemented in GWAMA v2.1.34 (20). Post meta-
analysis, SNPs with MAF < 5%, available in less than six studies, with large absolute values 
of beta coefficients and standard errors (≥ 10) were excluded (Supplementary Figure 1). 
Heterogeneity was assessed using the I2 metric from the complete study-level meta-analysis. 
Between-study heterogeneity was tested using the Cochran Q statistic and considered 
significant at p < 0.1. We used the commonly accepted threshold of 5.0×10−8 for joint p 
values to determine statistical significance. Nominal significance was considered to be p < 
0.05. The CMplot package (21) in R was used to generate Manhattan and quantile-quantile 
plots. Regional plots around genome-wide or suggestive genes were visualized using 
LocusZoom (22). The final meta-analysis included 5,385,635 common autosomal SNPs from 
5,485 independent individuals of European ancestors treated with sulfonylureas (λ=1.008) 
(Supplementary Figure 2). 
 
Common variant heritability  
We used the generalized restricted maximum likelihood (REML) approach under the LDAK 
assumptions using SumHer v5.1 (23) to estimate how much of the variance in HbA1c 
reduction after sulfonylurea treatment could be attributed to common genetic variants (SNP-
based heritability, h2 SNP). This method is a valid approach for estimating heritability in 
studies in which familial data with the same diagnosis who have received the same 
medication and assessed using the same treatment outcome is not feasible. In addition, 
SumHer uses GWAS summary without requiring individual-level data (23). Therefore, we 
estimated the SNP-heritability using summary statistics from the meta-GWAS. In order to 
avoid the impact of extreme linkage disequilibrium (LD) regions and disproportionately large 
effect size SNPs on heritability estimates, we exclude SNPs within the MHC (Chromosome 
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6: 25-34 Mb) and SNPs which individually explain >1% of phenotypic variation and SNPs in 
LD with these (within 1 cM). 
 
Conditional Analysis 
Given rs10770791 is in partial LD with previously established nonsynonymous variants, 
rs4149056 (*5; V174A, D'=1; r2=0.17) and rs2306283 (*1B; N130D, D'=0.98; r2=0.63), we 
performed conditional analysis by including these SNPs in the model together. This analysis 
was carried out with individual-level data from the GoDARTS and PMET cohorts (65% of 
the total population) and baseline HbA1c, PCs and other study specific covariates. 
 
Biochemical response to glipizide 
To test weather meta-GWAS identified genetic variants are associated with trough glucose 
levels, we performed a lookup using data from the Study to Understand the Genetics of the 
Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). SUGAR-MGH 
enrolled 1,000 participants at risk of anti-diabetic therapy in the future or individuals with 
lifestyle-controlled type 2 diabetes who are naïve to treatment. Participants received a single 
dose of 5 mg glipizide followed by measurement of glucose and insulin levels at 30, 60, 90, 
120, 180, and 240 minutes. This was used to construct phenotypes of acute glipizide 
response. The association between rs1234032 and rs10770791 with glipizide response was 
performed using linear regression with baseline glucose, age, sex, and the first 10 PCs as a 
covariate (see supplementary note). 
 
Drug-drug gene interaction analysis 
11 
 
Given we have identified a genetic variant in the SLCO1B1 (a gene encoding hepatic 
transporter of statins) associated with glycaemic response to sulfonylureas, we checked for 
interaction between SLCO1B1-rs10770791 and statin use in a drug-drug-gene interaction 
model using linear regression, with HbA1c reduction as the dependent variable. This analysis 
was performed using individual-level data from the GoDARTS and PMET cohorts where we 
have access to prescription data.  
Statin treated cases were recipients of sulfonylurea who were also prescribed statins for at 
least the three months prior to the measurement of treatment HbA1c.  Statin untreated 
controls were those recipients of sulfonylurea who did not receive a statin prescription at least 
for one year prior to measurement of the treatment HbA1c. 
 
Expression quantitative trait locus lookups  
Expression quantitative trait loci (eQTL) analysis seeks to identify genetic variants that affect 
the expression of one or more genes: a gene-SNP pair for which the expression of the gene is 
associated with the allelic configuration of the SNP is referred to as an eQTL. eQTL lookups 
were performed in human liver and whole blood samples for rs10770791 and rs1234032, 
respectively. Additional lookups were performed using publicly available data from the 
GTEx consortium. 
The human liver eQTL lookups were carried out using data from previous study performed 
by Dr. Federico Innocenti’s group (24). In brief, this eQTL study was performed with 1,183 
liver samples, combined from four dataset (24). We looked up the top associated SNP, 
rs10770791, from this study, as it is in the SLCO1B1 and SLCO1B3 region, which are genes 
that are abundantly expressed in the liver.  
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The human whole blood eQTL lookup was performed using data from the DIRECT 
consortium in a total of 3, 029 subjects who are at high risk of developing type 2 diabetes or 
recently diagnosed type 2 diabetes (25). Detailed explanation of the eQTL analysis is 
previously published (26) and summary statistics are available in the following DOI: 
10.5281/zenodo.4475681  
 
Cell culture and in vitro transport and inhibition studies 
HEK293 Flp-In cells stably expressing empty vector (EV), OATP1B1, OATP1B3, were used 
to perform in vitro transport and inhibition studies to establish the potency of inhibitors as 
IC50 (i.e., concentration of inhibitor required to inhibit 50% uptake of a particular OATP1B1 
and OATP1B3 substrate). Stably transfected HEK-293 Flp-In cells were maintained in 
Dulbecco’s Modified eagle medium H-21 medium supplemented with 10% fetal bovine 
serum, 100 units/mL penicillin, 100 units/mL streptomycin, and 500 µg/mL Geneticin. For 
transport studies, 150,000 cells/well were seeded the day before experiment on a poly-d-
lysine coated 48-well plate.  After 16-24 hours, media were removed and cells were 
incubated at 37°C for 5-10 min in 0.5 mL Hank’s Balanced Salt Solution (HBSS) 
(ThermoFisher Scientific). Uptake studies were initiated after removing 0.3 mL HBSS above 
and adding 0.15 mL of HBSS containing trace amount of 3H-glyburide (Perkin Elmer, 
NET1024250UC)) or 3H-glipizide (Moravek, MT1855) or 3H-esterone sulfate (as positive 
control, Perkin Elmer NET203250UC).  After 5 minutes, radioactive substrates were 
removed and washed twice with 1 mL of ice cold HBSS.  For inhibition studies, same 
methods above were used, where 3H-glyburide was used as substrate and various 
concentrations of atorvastatin (Cayman) or simvastatin (Cayman) were added together with 
3H-glyburide. To compare the uptake of 3H-glyburide and 3H-glipizide in OATP1B1 
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reference and OATP1B1-174A (*5) expressing cells, studies were performed using stable and 
transiently transfected cells. The stable and transient experiments were carried out using 
HEK293 Flp-In cell lines expressing EV, OATP1B1-reference and OATP1B1-174A (*5) 
previously established by our group (27). These cell lines were used to determine the uptake 
of 3H-glyburide, 3H-glipizide and 3H-esterone sulfate (as positive control).  In brief, each 
well was transfected with 200 ng of the DNA vector with 0.4 µL of Lipofectamine LTX 
transfection reagent (ThermoFisher) in a 48-well poly-d-lysine coated plate. Uptake studies 
were then performed after 48 hours using the methods described above and in triplicate wells. 
 
Results 
Glycemic response to sulfonylureas is heritable 
The SNP heritability estimate (h2) for a model-adjusted absolute reduction in HbA1c was 
37±11%, comparable to our previous estimate for metformin (h2=34%) (14). This suggests 
that about one third of the total variance of glycemic response to sulfonylureas is due to the 
additive effects of common variants. 
 
GWAS identifies two variants associated with altered glycemic response to sulfonylureas 
Meta-GWAS identified two genome-wide significant variants, rs1234032 and rs10770791, 
both on chromosome 12 (Figure 1, Supplementary Figure 2, Table 1). The most significant 
association was obtained for rs1234032, with a -0.14±0.03% (-1.5±0.3 mmol/mol) difference 
in HbA1c reduction per C-allele, p=2.39×10−8. No statistical evidence for difference in effect 
size between studies was observed (phet = 0.55) (Figure 3). We then examined data from a 
healthy volunteer population (SUGAR-MGH, N = 857) given a single dose of glipizide (28) 
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and found that the C-allele of rs1234032 was associated with higher post-dose glucose trough 
levels (β=1.61, p=0.005), and thus worse response, consistent with our GWAS findings. 
rs1234032 is an intergenic SNP, near GXYLT1 (Figure 2, Figure 3), a gene that encodes a 
xylose transferase. rs1234032 is a cis-eQTL to GXYLT1 in the whole blood using 3, 029 
samples from the DIRECT consortium, with the C-allele being associated with increased 
expression (β=0.21, p=2.04×10-58). rs1234032 also showed a significant association with 
GXYLT1 expression in multiple tissues including adipose subcutaneous (p=8.1×10-5), artery 
tibial (p=2.8×10-9), artery aorta (p=3.4×10-6), nerve tibial (p=3.6×10-6) and whole blood 
(p=0.01) from the GTEx consortium (29), with the C-allele associated with increased 
expression. These significant eQTL analyses could be due to strong linkage of rs1234032 
(D’=1 and R2=0.95) to rs7958582, which is within the cis-regulatory elements 
(https://screen.wenglab.org/). The C-allele of rs1234032 is also in LD with the A-allele of 
rs7964383 (D’=0.98, r2=0.41), which is highly associated with increased whole blood gene 
expression (p=1.7×10-4) (29) and circulating protein levels of GXYLT1 (30). Both rs7958582 
(β per G allele = -0.10, p = 1.84×10-06) and rs7964383 (β per A allele = -0.06, p = 0.003) 
were also nominally associated with glycaemic response to sulfonylureas.  
 
The second variant, rs10770791, is located in an intron of SLCO1B1 (Figure 2), and each 
copy of the C-allele (frequency 49.8%) was associated with a 0.11±0.02% (1.2±0.2 
mmol/mol) greater HbA1c reduction, p=4.80×10−8. Stratified analyses showed a consistent 
direction of association across cohorts with similar effect sizes with no significant 
heterogeneity (phet=0.94) (Figure 3). rs10770791 genotype was not significantly associated 
with sulfonylurea dose modification (p=0.16) or drug group (the likelihood of being on mono 
or dual therapy) (p=0.29). No significant association between rs10770791 and post-glipizide 
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trough glucose concentration was observed in healthy volunteers given glipizide in SUGAR-
MGH (β = -0.37, p= 0.46). 
 
rs10770791 is an eQTL for SLCO1B1 that encodes OATP1B1, a transporter of sulfonylureas 
Focusing on the SLCO1B1 locus, we performed locus-wide meta-analysis to identify the 
candidate causal gene (Figure 2). We also examined two established common 
nonsynonymous variants in SLCO1B1, rs4149056 (*5; V174A) and rs2306283 (*1B; 
N130D) (30). rs4149056 (D'=1; r2=0.17) and rs2306283 (D'=0.98; r2=0.63) were in partial 
LD with rs10770791, with both rs4149056 (β=0.10±0.03% (1.1±0.3 mmol/mol), p=2.72 
×10−4) and rs2306283 (β=0.08±0.02% (0.9±0.2 mmol/mol), p=4.32×10−5) nominally 
associated with sulfonylurea response. However, in a conditional analysis where we have 
individual level data from the GoDARTS and PMET cohorts, n=3,557 (65% of the total 
population), only rs10770791 remained strongly associated with sulfonylurea response 
(β=0.15±0.05% (2±0.4 mmol/mol), p=1.4×10−3); with rs4149056 (β=0.03±0.05% (0.3±0.4 
mmol/mol), p=0.58) and rs2306283 (β=0.06±0.05% (0.7±0.4 mmol/mol), p=0.19) not 
significant.  
We then undertook eQTL lookups of SLCO1B1 expression in 1,183 liver samples of 
European ancestry (24) and demonstrated that the C-allele of rs10770791 was associated with 
decreased SLCO1B1 expression (beta =-5.24, p=1.61×10−7) and marginally with decreased 
SLCO1B3 expression (beta =-2.46, p=0.01). We found directionally consistent but non-
significant associations in the 208 liver samples examined by the GTEx project (beta = -0.06, 




Glyburide is a substrate of both OATP1B1 and OATP1B3 (31-35), whereas there are 
conflicting reports about glipizide, which has been shown to be a substrate of OATP1B3, but 
not OATP1B1 (31). We therefore undertook functional studies on sulfonylurea transport and 
observed that both glyburide and glipizide were substrates of OATP1B1 and OATP1B3 in 
HEK293 cells recombinantly expressing the transporters (Figure 4A). Further, we observed 
that OATP1B1-Ala174 (c.521C) had a significantly lower uptake of glyburide (p<0.002) and 
a trend towards a lower uptake of glipizide (p=0.06) compared to OATP1B1-Val174 
(c.521T) (Figure 4B).  
 
Statins inhibit sulfonylurea transport via OATP1B1; genetically reduced OATP1B1 transport 
has a large effect in non-statin users. 
Given the high frequency with which hypercholesterolaemia and diabetes co-occur, statins 
are often taken concomitantly with sulfonylureas. OATP1B1, expressed on the basolateral 
membrane of human hepatocytes (36), contributes to the hepatic uptake of sulfonylureas and 
statins from portal blood (37). We therefore sought to examine whether the initiation of 
statins in patients receiving sulfonylurea is associated with glycemic response in a drug-drug-
gene interaction model with a sample of 3,566 adults, where we have access to individual 
level data. Using retrospective data from the GoDARTS and PMET cohorts; 2,096 (59%) 
sulfonylurea users were co-prescribed statins and 1,470 (41%) were not. In a multiple linear 
regression model adjusted for baseline HbA1c, statin co-treatment was associated with 
greater HbA1c reduction on initiation of sulfonylurea, but only when adjusted for rs10770791 
(0.22±0.09% (2±1.0 mmol/mol), p=0.02). These results highlight a significant interaction 
between statin use and SLCO1B1 genotype (rs10770791) (p=0.001) (Supplementary Table 
4). In support of these results, we show that atorvastatin acid and simvastatin acid inhibited 
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OATP1B1 and OATP1B3-mediated uptake of glyburide with IC50 values ranging between 
0.2 and 2.9 µM (Supplementary Table 5), consistent with previous studies showing that these 
two statins inhibit OATP1B1-mediated uptake of estradiol-17ß-glucuronide (38).  
 
We then performed stratified analysis to see if statin use modifies the association between 
rs10770791 and sulfonylurea related HbA1c reduction using a similar model. We observed 
that the effect of rs10770791 was abolished in sulfonylurea users prescribed statins 
(β=0.053±0.03% (0.6±0.3 mmol/mol), p=0.11). However, among users of sulfonylureas 
without statins, we found a pronounced HbA1c reduction associated with the C-allele of 
rs10770791 (β=0.23±0.049% (2.4±0.6 mmol/mol), p=3.1×10-6) (Supplementary Table 6). C-
allele homozygotes at rs10770797 had a 0.48±0.12% (5.2±1.26 mmol/mol) greater absolute 
HbA1c reduction than T-allele homozygotes.  
 
Discussion  
We report the first meta-GWAS on glycemic response to sulfonylureas and establish that this 
trait is heritable with a 37% heritability estimate. We have identified two novel loci at 
chromosome 12 and confirmed a potential involvement of the GXYLT1 and SLCO1B1 genes 
in glycemic response to sulfonylureas. We report large clinical effects of variants in 
SLCO1B1, which encodes a transporter for sulfonylureas in the liver where it is metabolised, 
and report interaction with co-prescription of statins.   
 
The SNP rs1234032 is an eQTL for GXYLT1 in multiple tissues including whole blood. 
GXYLT1 adds the first xylose to O-glucose-modified residues in NOTCH1 (31), which is a 
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major determinant of pancreatic islet cell mass and insulin secretion, and is a risk factor for 
diabetes (32). The C allele at rs1234032 was associated with increased expression of 
GXYLT1. Transgenic overexpression of human GXYLT1 was previously shown to impair 
Notch signalling (39). Notch signalling pathway is known to play an important role in 
regulating development of pancreas and also shown to be expressed in adult pancreas (40). A 
recent study by Eom et al compared glucose levels, insulin secretion, islet and β-cell masses 
in Notch1 antisense transgenic (NAS) and control mice after intraperitoneal glucose tolerance 
test. This showed higher glucose levels, lower insulin secretion, decreased total islet and β-
cell masses in NAS than the control mice. In line with this, we have shown increased trough 
glucose concentration with the C-allele in healthy volunteers who were naïve to type 2 
diabetes medications who received a glipizide challenge and hence worse response.  
The C allele at rs10770791 was significantly associated with reduced expression of SLCO1B1 
mRNA in the liver and worse glycemic response to sulfonylureas. SLCO1B1 encodes the 
organic anion-transporting polypeptide, OATP1B1, which facilitates the hepatic uptake of 
clinically relevant drugs such as statins. Gliclazide, glipizide, glyburide (glibenclamide), 
glimepiride, tolazamide and tolbutamide were prescribed for the subjects in this study. 
Around 90% of the prescriptions in the GoDARTS were for gliclazide and glipizide was the 
main sulfonylurea in the PMET cohorts. While gliclazide and glimepiride are substrates of 
OATP1B1 (31, 34), glyburide is shown to be a substrate of both OATP1B1 and OATP1B3 
(31, 34-36, 41, 42). However, there are conflicting reports about glipizide, which has been 
shown to be a substrate of OATP1B3, but not OATP1B1 (36). Here we showed that both 
glyburide and glipizide were substrates of OATP1B1 and OATP1B3. Further, we observed 
that OATP1B1-Ala174 (c.521C) had a significantly lower uptake of glyburide (p<0.002) and 
a trend towards a lower uptake of glipizide (p=0.06) compared to OATP1B1-Val174 
(c.521T). Examination of other known missense variants (rs60140950 (p.Gly256Ala), 
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rs11045681 (p.Tyr311Ser), rs11045819 (p.Pro155Thr)) in the SLCO1B3 and SLCO1B3-
SLCO1B7 regions that are in partial LD with rs10770791 showed no significant association. 
Taken together these results suggest that the pharmacogenetic mechanism for the effect of 
rs10770791 on sulfonylurea response is primarily a result of altered hepatic expression of 
SLCO1B1 and to a lesser extent, SLCO1B3. Partial LD of rs10770791 with various missense 
variants may contribute to its effect on sulfonylurea response; however, conditional analysis 
demonstrated association of rs10770791 with glycaemic response independent of the 
missense variants. The reduced SLCO1B1 expression likely results in less OATP1B1-
mediated transport of sulfonylurea into the liver and potentially higher plasma concentrations 
available at the site of action (pancreas). 
 
There is a high prevalence of multimorbidity and subsequent polypharmacy in type 2 
diabetes, highlighting a need to consider drug-drug as well as drug-drug-gene interactions in 
prediction models of glycaemic response to sulfonylureas. Given that statins are often taken 
concomitantly with sulfonylureas with both being substrates of OATP1B1, we examined for 
a possible drug-drug-gene interaction and showed a significant interaction between statin use 
and SLCO1B1 genotype (rs10770791) (p=0.001). Stratified analysis by statin use showed 
differential effects of rs10770791 in statin users and non-users. While the association 
between rs10770791 and glycemic response to sulfonylureas was abolished in statin users, it 
was more pronounced in statin non-users. In those not treated with statins nearly a quarter of 
the population who carry two C alleles at rs10770791 had a 0.48% (5.2 mmol/mol) greater 
HbA1c reduction compared to T allele homozygotes. These large effects are the equivalent of 
starting a DPP4 inhibitor (43) and equated to a dose difference of 28 mg of gliclazide. Our 
findings suggest that the previous reported observational association between statins and 
hypoglycemia in sulfonylurea users (44) may be explained by interactions at SLCO1B1, 
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depending on the underlying genotype. The findings are consistent with previous studies in 
healthy volunteers and rodents demonstrating that atorvastatin administration is associated 
with increased levels of glimepiride (45) and glyburide (46), respectively. Given there is a 
strong recommendation to use statins by recent guidelines, statin use is increasing among 
people with diabetes (47). Therefore, integrating co-medications with genetic data could 
improve optimisation of polypharmacy regimens. 
 
This study has some limitations. First, the modest sample size does not have sufficient power 
to detect the contribution of rare and low frequency variants in heritability estimation and/or 
glycemic response to sulfonylureas. However, this is the first GWAS and largest 
pharmacogenomic study on sulfonylureas response so far. Second, this study was conducted 
in whites of European descent, and therefore the results may not generalize to other 
populations. Third, even though we have performed several validation studies, direct 
replication of the findings in an independent study is warranted. Finally, further studies need 
to be done to elucidate the biological mechanism of the identified associations especially for 
GXYLT1.  
 
In conclusion, we have established that common genetic variants contribute to the variation in 
glycemic response to sulfonylureas, with an estimated heritability of 37%. This result shows 
that a moderate proportion of the variance in glycemic response is genetic with an important 
role for common genetic variation in glycemic response to sulfonylureas. We report that a 
variant that modulates gene expression and circulating GXYLT1 reduces response to 
sulfonylureas. We have also revealed a robust association between rs10770791, a cis-eQTL 
for SLCO1B1 expression in the liver, and glycemic response to sulfonylureas, with reduced 
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SLCO1B1 expression associating with increased response to sulfonylureas. Our results 
suggest the potential of rs10770791 to be a biomarker for stratified medicine in diabetes. In 
addition, we have highlighted significant drug-drug-gene interactions between sulfonylurea, 
statin use and rs10770791, with clinically actionable genetic effects with pronounced 
differences in HbA1c reduction in a subgroup of patients treated with sulfonylureas without 
statins. Over the next 5 years we will see an ever-increasing availability of genotype or 
sequence data embedded in the medical records; given replication, the gene-statin interactions 
could be clinically actionable that will need to be taken into account at the point of 
prescribing sulfonylureas.   
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Tables and Figures  
Tables 
rsid Chr Position  Nearest gene *EA †NE
A 




rs1234032 12 42354629 GXYLT1 C T 0.252 -0.141429 0.025 2.39×10-8 7 0.55 4810 
rs10770791 12 21338406 SLCO1B1 C T 0.498 0.107475 0.020 4.80×10-8 8 0.93 5476 
rs2217693 12 21107376 SLCO1B3-
SLCO1B7 
G A 0.925 -0.188639 0.037 8.40×10-8 8 0.34 5479 
rs8062936 16 52475969 TOX3 G A 0.371 0.122292 0.023 1.57×10-7 7 0.39 4810 
rs7965567 12 21161025 SLCO1B3-
SLCO1B7 
T G 0.051 0.251377 0.051 7.81×10-7 6 0.57 4591 
rs7703659 5 83222316 LOC107986386 A G 0.132 -0.14596 0.030 1.15×10-6 8 0.30 5478 
rs1900362 13 85059600 LINC00333 G A 0.339 -0.102358 0.021 1.26×10-6 8 0.69 5475 
rs11816402 10 61491043 MRLN  T C 0.082 -0.217113 0.046 2.66×10-6 7 0.39 4810 
rs11667346 19 8817909 NFILZ G A 0.099 -0.194814 0.042 4.39×10-6 6 0.37 4591 
rs59012839 9 138419280 LCN1 G A 0.097 -0.216643 0.047 4.51×10-6 6 0.56 4210 
rs12928694 16 10067543 GRIN2A A C 0.159 -0.123792 0.027 5.52×10-6 8 0.56 5475 
rs58013952 19 29917652 LOC284395 T C 0.115 0.160896 0.036 5.78×10-6 7 0.56 4810 
rs75553467 1 74014130  LINC02238 C G 0.059 -0.233071 0.052 6.31×10-6 6 0.48 4591 
rs73239453 4 14122932 LINC01085 T C 0.106 0.160255 0.036 8.69×10-6 7 0.93 4810 
rs10250448 7 33489223 BBS9 G A 0.10 0.15 0.03 8.94×10-6 8 0.78 5479 
*EA: Effective allele, †NEA: Non-effective allele, ‡EAF: Effective allele frequency, §A negative beta implies that the effective allele is associated with 
reduced response to sulfonylureas.  
Table 1: Results for index variants in the top 15 independent loci (p<1.0×10-5) associated with glycaemic response identified in a GWAS meta-analysis of 




Figure 1: Manhattan plot of a genome-wide results from single marker association with glycemic response to 
sulfonylureas using an additive genetic model in a meta-analysis consisting of 5,485 individuals with type 2 
diabetes on sulfonylureas.    
Figure 2: Regional association plots around genome-wide significant SNPs, rs1234032 (left) and rs10770791 
(right) locus at chromosome 12 for the meta-GWAS. The purple diamonds in both plots indicate the top SNPs in 
the locus.  
Figure 3: Forest plot of the meta-analysis of the association of HbA1c reduction with rs1234032 (left) and 
rs10770791 (right) variants after sulfonylurea treatment.  Information on the various cohorts can be found in 
supplemental information. The numbers in parentheses indicate the number of individuals in each of the cohorts. 
The last column shows the effect size and [95% confidence interval] 
Figure 4: Glyburide and glipizide uptake in HEK293-FlpIn cells recombinantly expressing SLCO1B1 or 
SLCO1B3. (A) Uptake of [3H]-glyburide and [3H]-glipizide in HEK293-FlpIn stable cells expressing vector 
only (EV), SLCO1B1 or SLCO1B3. Rifampicin (50 µM) is used as a canonical inhibitor of SLCO1B1 and 
SLCO1B3 (Sudsakorn et al., 2020). P-values, representing significance from EV, were determined by one-way 
analysis of variance followed by Dunnett’s two-tailed test. **** p<0.0001; *** p<0.001; ** p<0.01; * p<0.05. 
Bars represent the mean ± SEM uptake from three wells. Values shown are from a representative experiment of 
at least three independent studies. (B) Uptake of [3H]-estrone sulfate, [3H]- glyburide and [3H]-glipizide in 
HEK293-FlpIn stable cells expressing vector only, SLCO1B1 and SLCO1B1-V174A. Estrone sulfate is a 
canonical substrate of SLCO1B1 and is used as a positive control in this assay. P-values, assessing significance 
from EV, were determined by one-way analysis of variance followed by Dunnett’s two-tailed test. **** 
p<0.0001; *** p<0.001; ** p<0.01; * p<0.05. Bars represent the mean ± SEM uptake from four wells from a 
representative experiment. The uptake values for [3H]- glyburide and [3H]-glipizide shown are from at least 
four independent studies with three or four replicates per study. (C) Inhibition of [3H]- glyburide uptake by 
atorvastatin and simvastatin acid in HEK293-FlpIn stable cells expressing SLCO1B1 and SLCO1B3. Each point 
represents the mean ± SEM uptake from four wells. Values shown are from a representative experiment of two 
independent studies. 
 
 
 
 
 
 
 
 
 
 
 
 




